Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
企業コードCELG_r
会社名Bristol-Myers Squibb Co
上場日Mar 17, 1980
最高経営責任者「CEO」Dr. Christopher S. (Chris) Boerner, Ph.D.
従業員数- -
証券種類- -
決算期末- -
本社所在地Route 206 And Province Line Road
都市PRINCETON
証券取引所- -
国United States of America
郵便番号08543
電話番号16092524621
ウェブサイトhttps://www.bms.com
企業コードCELG_r
上場日Mar 17, 1980
最高経営責任者「CEO」Dr. Christopher S. (Chris) Boerner, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし